BRPI0406819A - Conjugados obtidos por aminação redutora do poli-sacarìdeo capsular do pneumococo de sorotipo 5 - Google Patents

Conjugados obtidos por aminação redutora do poli-sacarìdeo capsular do pneumococo de sorotipo 5

Info

Publication number
BRPI0406819A
BRPI0406819A BR0406819-0A BRPI0406819A BRPI0406819A BR PI0406819 A BRPI0406819 A BR PI0406819A BR PI0406819 A BRPI0406819 A BR PI0406819A BR PI0406819 A BRPI0406819 A BR PI0406819A
Authority
BR
Brazil
Prior art keywords
pneumococcal capsular
aminated
type
conjugates
hpaec
Prior art date
Application number
BR0406819-0A
Other languages
English (en)
Inventor
Noulle Mistretta
Emilie Danve
Monique Moreau
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of BRPI0406819A publication Critical patent/BRPI0406819A/pt
Publication of BRPI0406819B1 publication Critical patent/BRPI0406819B1/pt
Publication of BRPI0406819B8 publication Critical patent/BRPI0406819B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"CONJUGADOS OBTIDOS POR AMINAçãO REDUTORA DO POLI-SACARìDEO CAPSULAR DO PNEUMOCOCO DE SOROTIPO 5". A invenção tem por objeto conjugados oriundos da aminação redutora do poli-sacarídeo capsular do pneumococo de sorotipo 5. As condições de aminação redutora se distinguem das condições clássicas pelo fato de permitirem evitar o aparecimento de um composto, indesejável que é prejudicial à imunogenecidade dos conjugados. Em espectrometria RMN do Carbono, esse composto indesejável se caracteriza por um sinal de ressonância entre 13 e 14 ppm. Os poli-sacarídeos aminados que entram na produção dos conjugados possuem, portanto, um espectro RMN do Carbono desprovido de sinal de ressonância entre 13 e 15 ppm. As condições de aminação redutora oferecidas pela invenção são em número de duas. De acordo com um primeiro processo, a aminação redutora é conduzida com pH ligeiramente ácido (4-6,5) durante no máximo 4 horas. De acordo com um segundo processo, o poli-sacarídeo é inteiramente reduzido, depois fragmentado e enfim submetido a uma aminação redutora propriamente dita, em condições clássicas ou não. De acordo com o processo aplicado, a estrutura do poli-sacarídeo aminado pode variar (conversão ou não do resíduo Sug da unidade repetitiva em quinovosamina N-acetilada e em fucosamina N-acetilada); mas essas variações, tais como registradas em espectrometria RMN do Carbono, não têm efeito sobre a imunogenicidade.
BRPI0406819-0A 2003-01-17 2004-01-16 Psycho-capacular polycarbonate of the type 5 pneumococo aminated at the level of the aldeed group completes, its conjungate, pharmaceutical composition the comprehension and its production process, as well as processes of production of a formula conjugate of ps-ch2-nh- ch 2 -nh-s ???????? - p. BRPI0406819B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR03/00488 2003-01-17
FR0300488A FR2850106B1 (fr) 2003-01-17 2003-01-17 Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
PCT/FR2004/000089 WO2004067574A1 (fr) 2003-01-17 2004-01-16 Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5

Publications (3)

Publication Number Publication Date
BRPI0406819A true BRPI0406819A (pt) 2005-12-27
BRPI0406819B1 BRPI0406819B1 (pt) 2017-01-03
BRPI0406819B8 BRPI0406819B8 (pt) 2021-05-25

Family

ID=32605815

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0406819-0A BRPI0406819B1 (pt) 2003-01-17 2004-01-16 Psycho-capacular polycarbonate of the type 5 pneumococo aminated at the level of the aldeed group completes, its conjungate, pharmaceutical composition the comprehension and its production process, as well as processes of production of a formula conjugate of ps-ch2-nh- ch 2 -nh-s ???????? - p.

Country Status (13)

Country Link
US (1) US7812006B2 (pt)
EP (1) EP1590373B1 (pt)
KR (1) KR101044437B1 (pt)
AT (1) ATE520718T1 (pt)
AU (1) AU2004207647B2 (pt)
BR (1) BRPI0406819B1 (pt)
CA (1) CA2512847C (pt)
DK (1) DK1590373T3 (pt)
FR (1) FR2850106B1 (pt)
IL (1) IL169689A0 (pt)
MX (1) MXPA05007533A (pt)
NZ (1) NZ541254A (pt)
WO (1) WO2004067574A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000278267A1 (en) * 2000-09-01 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vibrio cholerae o139 conjugate vaccines
TWI445545B (zh) * 2005-04-08 2014-07-21 Wyeth Corp 多價肺炎球菌多醣-蛋白質共軛物組合物
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
US9522382B2 (en) * 2011-09-06 2016-12-20 Biologistics Llc Affinity/lectin chromatography methods
CN103917245B (zh) * 2011-09-14 2017-06-06 葛兰素史密丝克莱恩生物有限公司 用于制备糖‑蛋白质糖缀合物的方法
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10596272B2 (en) 2015-06-08 2020-03-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Vaccines against Streptococcus pneumoniae serotype 5
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
EP3585427A4 (en) * 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
PE20201338A1 (es) 2017-12-06 2020-11-25 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos
CN113453708A (zh) 2018-12-19 2021-09-28 默沙东公司 包含肺炎链球菌多糖-蛋白缀合物的组合物及其使用方法
US20230405137A1 (en) * 2020-11-10 2023-12-21 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
FR2682388B1 (fr) 1991-10-10 1995-06-09 Pasteur Merieux Serums Vacc Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
JPH08511007A (ja) 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
EP1035137A1 (en) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Method for the reductive amination of polysaccharides
EP1163000B1 (en) 1999-03-19 2008-02-27 GlaxoSmithKline Biologicals S.A. Vaccine against antigens from bacteriae

Also Published As

Publication number Publication date
AU2004207647A1 (en) 2004-08-12
FR2850106A1 (fr) 2004-07-23
KR20050093838A (ko) 2005-09-23
WO2004067574A1 (fr) 2004-08-12
US7812006B2 (en) 2010-10-12
CA2512847C (en) 2012-08-21
ATE520718T1 (de) 2011-09-15
KR101044437B1 (ko) 2011-06-27
NZ541254A (en) 2008-07-31
AU2004207647B2 (en) 2010-07-01
EP1590373A1 (fr) 2005-11-02
FR2850106B1 (fr) 2005-02-25
US20040170638A1 (en) 2004-09-02
BRPI0406819B1 (pt) 2017-01-03
BRPI0406819B8 (pt) 2021-05-25
CA2512847A1 (en) 2004-08-12
DK1590373T3 (da) 2011-12-05
IL169689A0 (en) 2007-07-04
MXPA05007533A (es) 2005-12-05
EP1590373B1 (fr) 2011-08-17

Similar Documents

Publication Publication Date Title
IL169689A0 (en) Conjugates obtained by reductive amination of serotype 5 pneumococcus capsular polysaccharide
Lotan et al. Purification of wheat germ agglutinin by affinity chromatography on a Sepharose-bound N-acetylglucosamine derivative
DE50309087D1 (pt)
AR048035A1 (es) Conjugados de almidon de hidroxialquilo y una proteina, preparados por aminacion reductora
ATE369878T1 (de) Träger-pharmaka-konjugate
ATE497005T1 (de) Dna und spezifische proteine oder peptide der bakterienspezies neisseria meningitidis, verfahren zu deren herstellung und biologische anwendungen
WO2005072778A3 (en) Use of amino-oxy functional groups in the preparation of vaccines conjugates
TW200633719A (en) Glycoconjugate vaccines containing peptidoglycan
PT1282663E (pt) Gel constituido por um poli-alfa-1,4-glucano e amido
WO2002050122A3 (en) Means for the diagnosis and therapy of ctcl
SE0402322D0 (sv) Method of preparing a chromatography matrix
WO2007124439A3 (en) Diagnosis of stroke using metalloproteinase or transaminase
TW200718426A (en) Stable lyophilized anthracycline glycosides
CA2836154C (en) Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
DE69523296T2 (de) Molkeprotein/polysaccharide Gel, hergestellt durch Hochdruckbehandlung
DE60315827D1 (de) Verbesserte polysaccharid- und glykokonjugat-vakzine
WO2005003775A3 (en) Glycoconjugates and their use as potential vaccines against infection by shigella flexneri
PT1165489E (pt) Processo para a preparacao de gabapentina
Kawaguchi et al. Occurrence of Galβ (1å3) GalNAc-SerThr in the linkage region of polygalactosamine containing fungal glycoprotein from Cordyceps ophioglossoides
BR0213771A (pt) Molécula de ácido nucleico isolada, vetor, célula hospedeira, e, método para a preparação de um composto de quìmica fina
WO2005032491A3 (en) Methods and compositions for mycoplasma pneumoniae exotoxins
Blomberg et al. Immobilization of reducing oligosaccharides to matrices by a glycosylamide linkage
Roy et al. Michael addition of poly-L-lysine to N-acryloylated sialosides. Syntheses of influenza A virus haemagglutinin inhibitor and group B meningococcal polysaccharide vaccinest
Wu STRUCTURAL CONCEPTS Lea, Leb, I AND FROM
CL2007000839A1 (es) Procedimiento para producir un conjugado que comprende un polisacárido u oligosacárido de tipo 5 u 8 de s. aureus y una proteína portadora; conjugado inmunogénico que lo comprende; vacuna que comprende al conjugado; procedimiento de obtención de dicha vacuna; y uso del conjugado para tratar o prevenir la infección por estafilococos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 03/01/2017, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/01/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF